HBA-USA members that conduct research on "Cancer"
- Bioengineering
Leonidas Alexopoulos
Harvard Medical School / MIT, Postdoctoral Fellow
Bioengineering, Cancer, Computational Biology, Systems Biology
Currently I'm working on a collaborative effort between MIT, HMS, and Pfizer to explore signaling networks of liver cells using a systems biology approach.
Applications of this research is on drug development, efficacy, and toxicity. I have also accepted a lecturer position at the National Technical University
of Athens (starting on Feb 2008). My research in Athens will focus on systems biology and bioengineering.
leonidas@mit.edu
Leonidas Bleris
Harvard FAS Center for Systems Biology, Postdoctoral Fellow
Cancer, Bioengineering, Gene Therapy
lbleris@cgr.harvard.edu
Christos Hatzis
Nuvera Biosciences, Vice President of Technology
Personalized medicine, diagnostics for therapy selection in cancer
christos@nuverabio.com
Sotirios Kampranis
Tufts University School of Medicine, Instructor
Structure, Epigenetic Regulation of Gene Expression and Cancer, Metabolic Engineering
s.kampranis@gmail.com
Triantafyllos Stylianopoulos
Massachusetts General Hospital-Harvard Medical School, Post-doctoral Researcher
The goal of my research is to develop novel computational methods for the study of mass and fluid transport through the extracellular matrix of tumors with the intention
of improving drug delivery
styliano9@hotmail.com
Ioannis Zervantonakis
Massachusetts Institute of Technology, Graduate student
Microfluidics, Tissue Engineering, Mechanical Engineering
zervanto@mit.edu
- Biostatistics
Alexia Iasonos
Memorial Sloan Kettering Cancer Center, Assistant Attending Biostatistician
Biostatistics, Cancer, Surgery
- Breast & Endometrial Cancer
Marios A Gavrielides
FDA, Research Fellow
Marios A. Gavrielides received his Bachelor's degree and Master's degree in Electrical Engineering in 1994 and 1996 respectively at the University of
South Florida, Tampa Florida, and a Ph.D. in Biomedical Engineering from Duke University, Durham, North Carolina, in 2001. He was a recipient of a
Susan G. Komen Breast Cancer foundation Dissertation Award in 2000 for his PhD thesis work on automatic diagnosis of breast cancer. From 2002 to 2004
he was a postdoctoral researcher at the Department of Informatics at the Aristotle University of Thessaloniki, Thessaloniki, Greece. Currently, he is a
Research Fellow at the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) and National Institute of
Biomedical Imaging and Bioengineering (NIBIB) Joint Laboratory for the Assessment of Medical Imaging Systems (LAMIS), at Rockville, Maryland. His
research interests include medical imaging processing and the development of ! computer-aided detection and diagnosis methods in the fields of digital
mammography, computed tomography, and microscopy imaging.
marios.gavrielides@fda.hhs.gov
Dimitris Iliopoulos (Member of the current Board of Directors)
BCMP Dept, School of Medicine, Harvard University Research Associate
Transcriptional networks, microRNAs in cancer
dimiliopou@yahoo.com
Miltos Kininis
Cornell University, PhD student
mk337@cornell.edu
Antonia Patsialou
Temple University, PhD student
apatsial@temple.edu
Athina Zacharia
Uniformed Services University of the Health Sciences, Research Scientist
1. Monitoring of the Immune Response to HER2/neu peptide vaccines in Breast Cancer patients (phase I and II clinical trials)
2. Complement-mediated Tissue injury and inflammation in Ischemia/Reperfusion
azacharia@usuhs.mil
- Cell Adhesion & Proliferation
Vasiliki Gkretsi
University of Pittsburgh School of Medicine
vag2+@pitt.edu
- Cell Biology
Spiro Getsios
Northwestern University Feinberg School of Medicine, Assistant Professor
Cancer, Cell-cell adhesion and communication pathways in development and disease
s-getsios@northwestern.edu
- Cell Cycle Regulation
Aristotelis Astrinidis
Drexel University College of Medicine, Research Assistant Professor
Pathogenesis of Tuberous Sclerosis Complex (TSC) and Lymphangioleiomyomatosis (LAM).
Regulation of cell growth, mitotic progression, and cytoskeleton.
http://www.pages.drexel.edu/~aa494
Aristotelis.Astreinidis@drexelmed.edu
Yiannis Bothos
University of Pennsylvania, Post-doctoral fellow
bothos@gmail.com
Thales Papagiannakopoulos
University of California, Santa Barbara, PhD candidate
With over 600 miRNA genes identified experimentally in the human genome and a plethora of computatiaonally predicted mRNA targets, it is believed that these small
RNAs have a central role in diverse cellular and developmental processes. Therefore aberrant expression of miRNA genes could lead to human disease, including
cancer. Studies from our group and other have confirmed that miRNAs regulate cell proliferation and apoptosis. Furthermore, these non-coding RNAs can control
cellular identity and mediate differentiation.
miRNAs are playing an important role in inducing and maintaining the oncogenic state of various types of cancer. This function lies within their ability to target multiple
transcripts including many tumor suppressor genes or oncogenes.
With the use of gliomas as a model, I aim to determine the role of miRNAs in epigenetically regulating oncogenesis and tumor maintenance.
papagian@lifesci.ucsb.edu
Elena Stavridi
University of Pennsylvania, Senior Scientist
stavridi@wistar.upenn.edu
Athanassios Vassilopoulos
NIDDK/NIH, Visiting Postdoctoral Fellow
Cell cycle, cancer stem cells
vassiloa@niddk.nih.gov
- Chemoprevention
George John Tsioulias
Mount Sinai School of Medicine, Clinical Assistant Professor
Cancer chemoprevention using animal models and clinical trials. cancer chemoprevention using animal models and clinical trials
tsiouliasg@hotmail.com
- Colon & Breast Cancer
Panos Papagiorgis
Boston University, PhD student in Genetics
ppapageo@bu.edu
- Endocrine Cancers
Nicholas J. Sarlis
Sanofi-Aventis, Medical Director, Oncology
Head & Neck Oncology, Taxane Clinical Pharmacology, Oncology Clinical Protocol Management, Drug Development
nicholas.sarlis@sanofi-aventis.com
- Genomic Alterations
Theodore G. Krontiris
Professor of Molecular Medicine
City of Hope Comprehensive Cancer Center, Director
Executive Vice-President for Medical & Scientific Affairs
tkrontiris@coh.org
- Head & Neck Cancer
Alexandros Georgolios
MD, Head and neck cancer, Genetics of Hearing loss
ageorgol@hotmail.com
Nicholas J. Sarlis
Sanofi-Aventis, Medical Director, Oncology
Head & Neck Oncology, Taxane Clinical Pharmacology, Oncology Clinical Protocol Management, Drug Development
nicholas.sarlis@sanofi-aventis.com
- Infectious Diseases
Dimitrios P. Kontoyiannis
The University of Texas MD Anderson Cancer Center, Associate Professor
Opportunistic Infections, Medical Mycology, Experimental Pharmacology, Molecular Mechanisms of Drug Resistance
dkontoyi@mdanderson.org
- Inflammation
Elias Gounaris
Dana Farber Cancer Institute, Research Fellow
Inflammation and cancer
Elias_Gounaris@dfci.harvard.edu
- Internal Medicine
Markos G Kashiouris
Johns Hopkins -- Sinai Hospital, Internal Medicine PGY1
Internal Medicine, Hematology/Oncology
- Invasion
Matthildi Valianou
Fox Chase Cancer Center, Research Associate
Identification and functional analysis of the murine fibroblast activation protein promoter region.
The long term goal is to identify regulators and function of this selectively expressed serine protease.
FAP has a tight expression pattern making it an elegant target for cancer therapy.
m_valianou@fccc.edu
- Leukemia & Multiple Myeloma
Efstratios Katsoulidis, Ph.D.
Northwestern University, Research Assistant Professor
Biological Chemistry, Cancer, Hematology, Immunology
-katsoulidis@northwestern.edu
Anastasios Raptis
raptisa@upmc.edu
- Lung Cancer
Konstantinos Arnaoutakis
Tufts University, Hematology-Oncology fellow
Supportive care clinical research , Bone health , Lung Cancer
karnaoutakis@massmed.org
Joanna Floros, PhD
Pennsylvania State University College of Medicine, Evan Pugh Professor of Pediatrics and Obstetrics & Gynecology, Director of The Penn State Center for Host
defense, Inflammation and Lung Disease (CHILD) Research
jfloros@psu.edu
DNA methylation of host defense molecules
Alexander Pertsemlidis
UT Southwestern Medical Center, Assistant Professor
We are interested in computational biology, specifically in identifying and characterizing mutations relevant to disease, and in microRNA roles in
cholesterol homeostasis and lung cancer pathogenesis
Alexander.Pertsemlidis@UTSouthwestern.edu
Vassiliki Saloura, MD
Hahnemann University Hospital, Resident
Oncolytic virotherapy in lung cancer and mesothelioma, molecular predictors of sensitivity to chemotherapy and personalized approach for chemotherapy in cancer
valsaloura@yahoo.com
- Malignant Mesothelioma
Poulikos Poulikakos
Memorial Sloan-Kettering Cancer Center, Research Fellow
poulikap@mskcc.org
Vassiliki Saloura, MD
Hahnemann University Hospital, Resident
Oncolytic virotherapy in lung cancer and mesothelioma, molecular predictors of sensitivity to chemotherapy and personalized approach for chemotherapy in cancer
valsaloura@yahoo.com
- Molecular Genetics
Nektarios Barabutis, MSc, PhD
Miami MIller School of Medicine, University of Miami, Postdoctoral fellow
Modifications of erythrocyte membrane proteins in patients with hereditary spaerocytosis.
Oxidative alterations of erythrocyte proteins in diabetic patients
The role of Reactive Oxygen Species (ROS) and Reactive Nitrogen Species (RNS) in cell physiology and metabolism.
The role and Signaling of Growth Hormone Releasing Hormone (GHRH) in cancer.
Effect of GHRH in ROS/RNS metabolism.
The role of Luteinizing Hormone Releasing Hormone (LHRH) in cancer and benign prostatic hyperplasia.
The role of GHRH agonistic and antagonistic analogs in human metabolism and disease.
nbarabutis@gmail.com
Vasileios Roukos
National Cancer Institute, National Institutes of Health, Post-doctoral fellow
Nuclear architecture and genome integrity
roukosv@mail.nih.gov
Sotirios G. Stergiopoulos
Harvard University School of Medicine, Clinical and Research Fellow
Cancer, Molecular Genetics
SGSTERGIOPOULOS@PARTNERS.ORG
- Nutrition
Maria Chondronikola
New York University, Graduate Student
Cancer, Nutrition
mc3128@nyu.edu
- Ocular Melanoma
Athanasios Papakostas
Massachusetts Eye & Ear Infirmary/ Harvard Medical School
THE ROLE OF MULLERIAN INHIBITING SUBSTANCE IN THE TREATMENT OF OCULAR MELANOMA-SNP ARRAY IN OCULAR MELANOMA
thanos_papakostas@meei.harvard.edu
- Ovarian Cancer
Angeliki Magklara
NIH/NCI
magklara@mail.nih.gov
- Pediatrics
Sosipatros A. Boikos
National Institute of Child Health and Human Development, National Institutes of Health, Research Associate Investigator-Post-doctoral fellow
Paediatric Endocrinology and Genetics, Cancer Cytogenetics,Carney Complex Syndrome
boikosso@mail.nih.gov
- Regulation of Apoptosis
Evripidis Gavathiotis
Dana-Farber Cancer Institute/Children's Hospital Boston, Harvard Medical School, Instructor
We study the structure and function of apoptotic protein interactions that regulate life and death decisions in the cell. We aim to develop novel pharmacological
strategies and compounds to prevent protein interactions that cause cancer and cardiovascular disease and translate them into therapies.
We employ a multidisciplinary approach spanning chemistry, structural biology, biochemistry, cell biology and in vivo studies.
evripidis_gavathiotis@dfci.harvard.edu
Antonis S. Zervos
University of Central Florida, Professor of Molecular Biology
azervos@mail.ucf.edu
- Stem cell therapy
Andreas Androutsellis-Theotokis
NINDS/NIH, Staff Scientist
Neural Stem Cells, Signal Transduction, Neuro-degenerative disease
My focus is on signal transduction pathways that are of particular importance to stem cells. The purpose of this focus is to identify mechanisms that activate
endogenous stem cells (for the purpose of regenerative interventions) and provide targets for novel anti-cancer approaches
AndreasTheotokis@gmail.com
Christos Tzimas
University of Pennsylvania, Post doctoral fellow
Cancer stem cells
chtzimas@gmail.com
- Vaccine development
Emmanuel Katsanis
University of Arizona Health Center, Professor
Department of Pediatrics
A novel anti-cancer vaccine has been developed in the laboratory (called Chaperone Rich Cell Lysate or CRCL) that has been shown to be effective
against a variety of tumors in mice. CRCL has a more pronounced immunologic effect per unit of protein than any of the individual HSP vaccines
currently used in clinical trials. We have found that it can stimulate potent tumor-specific T cell responses against a variety of tumors in mice.
Furthermore it has intrinsic adjuvant activity capable of stimulating both natural killer (NK) cells and dendritic cells (DC). Moreover, it can protect these
cells from regulatory T cell immunosuppression. Since tumor-derived CRCL vaccines are effective against a wide range of tumor types in mice, we have
embarked on in vitro human studies to confirm our findings. We have demonstrated that CRCL can be used effectively to pulse DCs and to generate
specific T cells against human cancer. This personalized vaccine is a promising approach for active cancer immunotherapy and merits further study in
humans.
- Waldenstrom’s Macroglobulinemia
Thea Ioakimidis
Dana Farber Cancer Institute, Researcher
Pharmaceutical Science
leukothea_ioakimidis@dfci.harvard.edu
- Wnt signaling
Meletios Verras
Stanford University, Postdoctoral fellow
Role of Wnt/beta-catenin signaling pathway in cancer
mverras@stanford.edu
- Other
Ourania Andrisani
Purdue University, Professor
Signal transduction mechanisms mediating liver and prostate cancer; signal transduction mechanisms involved in neural crest cell differentiation
andrisao@purdue.edu
Anastasia Kalea
Feinberg School of Medicine-Northwestern University, Postdoctoral Research Fellow
Diabetes complications; Trace minerals; Functional Foods; Vascular structure and function; Cancer, Public Health
a-kalea@northwestern.edu
David G Kalergis
Diffusion Pharmaceuticals LLC, CEO
Developing novel small molecules for the treatment of hypoxia related to ischemic conditions
dkalergis@diffusionpharma.com
Spiros P. Katsifis
University of Bridgeport, Professor and Chair
Metal interaction of physical and chemical agents in the induction of DNA damage. In Vitro mutagenesis - carcinogenesis
skatsif@bridgeport.edu
Stephanos Pavlides
Thomas Jefferson University, PhD candidate
Animal Science, Metabolic Diseases, Pulmonary Diseases, Cancer, Cardiovascular Disease, Muscle research, Pharmacology
spavlidescy@gmail.com
- Bioengineering
Leonidas Alexopoulos
Harvard Medical School / MIT, Postdoctoral Fellow
Bioengineering, Cancer, Computational Biology, Systems Biology
Currently I'm working on a collaborative effort between MIT, HMS, and Pfizer to explore signaling networks of liver cells using a systems biology approach.
Applications of this research is on drug development, efficacy, and toxicity. I have also accepted a lecturer position at the National Technical University
of Athens (starting on Feb 2008). My research in Athens will focus on systems biology and bioengineering.
leonidas@mit.edu
Leonidas Bleris
Harvard FAS Center for Systems Biology, Postdoctoral Fellow
Cancer, Bioengineering, Gene Therapy
lbleris@cgr.harvard.edu
Christos Hatzis
Nuvera Biosciences, Vice President of Technology
Personalized medicine, diagnostics for therapy selection in cancer
christos@nuverabio.com
Sotirios Kampranis
Tufts University School of Medicine, Instructor
Structure, Epigenetic Regulation of Gene Expression and Cancer, Metabolic Engineering
s.kampranis@gmail.com
Triantafyllos Stylianopoulos
Massachusetts General Hospital-Harvard Medical School, Post-doctoral Researcher
The goal of my research is to develop novel computational methods for the study of mass and fluid transport through the extracellular matrix of tumors with the intention
of improving drug delivery
styliano9@hotmail.com
Ioannis Zervantonakis
Massachusetts Institute of Technology, Graduate student
Microfluidics, Tissue Engineering, Mechanical Engineering
zervanto@mit.edu
- Biostatistics
Alexia Iasonos
Memorial Sloan Kettering Cancer Center, Assistant Attending Biostatistician
Biostatistics, Cancer, Surgery
- Breast & Endometrial Cancer
Marios A Gavrielides
FDA, Research Fellow
Marios A. Gavrielides received his Bachelor's degree and Master's degree in Electrical Engineering in 1994 and 1996 respectively at the University of
South Florida, Tampa Florida, and a Ph.D. in Biomedical Engineering from Duke University, Durham, North Carolina, in 2001. He was a recipient of a
Susan G. Komen Breast Cancer foundation Dissertation Award in 2000 for his PhD thesis work on automatic diagnosis of breast cancer. From 2002 to 2004
he was a postdoctoral researcher at the Department of Informatics at the Aristotle University of Thessaloniki, Thessaloniki, Greece. Currently, he is a
Research Fellow at the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) and National Institute of
Biomedical Imaging and Bioengineering (NIBIB) Joint Laboratory for the Assessment of Medical Imaging Systems (LAMIS), at Rockville, Maryland. His
research interests include medical imaging processing and the development of ! computer-aided detection and diagnosis methods in the fields of digital
mammography, computed tomography, and microscopy imaging.
marios.gavrielides@fda.hhs.gov
Dimitris Iliopoulos (Member of the current Board of Directors)
BCMP Dept, School of Medicine, Harvard University Research Associate
Transcriptional networks, microRNAs in cancer
dimiliopou@yahoo.com
Miltos Kininis
Cornell University, PhD student
mk337@cornell.edu
Antonia Patsialou
Temple University, PhD student
apatsial@temple.edu
Athina Zacharia
Uniformed Services University of the Health Sciences, Research Scientist
1. Monitoring of the Immune Response to HER2/neu peptide vaccines in Breast Cancer patients (phase I and II clinical trials)
2. Complement-mediated Tissue injury and inflammation in Ischemia/Reperfusion
azacharia@usuhs.mil
- Cell Adhesion & Proliferation
Vasiliki Gkretsi
University of Pittsburgh School of Medicine
vag2+@pitt.edu
- Cell Biology
Spiro Getsios
Northwestern University Feinberg School of Medicine, Assistant Professor
Cancer, Cell-cell adhesion and communication pathways in development and disease
s-getsios@northwestern.edu
- Cell Cycle Regulation
Aristotelis Astrinidis
Drexel University College of Medicine, Research Assistant Professor
Pathogenesis of Tuberous Sclerosis Complex (TSC) and Lymphangioleiomyomatosis (LAM).
Regulation of cell growth, mitotic progression, and cytoskeleton.
http://www.pages.drexel.edu/~aa494
Aristotelis.Astreinidis@drexelmed.edu
Yiannis Bothos
University of Pennsylvania, Post-doctoral fellow
bothos@gmail.com
Thales Papagiannakopoulos
University of California, Santa Barbara, PhD candidate
With over 600 miRNA genes identified experimentally in the human genome and a plethora of computatiaonally predicted mRNA targets, it is believed that these small
RNAs have a central role in diverse cellular and developmental processes. Therefore aberrant expression of miRNA genes could lead to human disease, including
cancer. Studies from our group and other have confirmed that miRNAs regulate cell proliferation and apoptosis. Furthermore, these non-coding RNAs can control
cellular identity and mediate differentiation.
miRNAs are playing an important role in inducing and maintaining the oncogenic state of various types of cancer. This function lies within their ability to target multiple
transcripts including many tumor suppressor genes or oncogenes.
With the use of gliomas as a model, I aim to determine the role of miRNAs in epigenetically regulating oncogenesis and tumor maintenance.
papagian@lifesci.ucsb.edu
Elena Stavridi
University of Pennsylvania, Senior Scientist
stavridi@wistar.upenn.edu
Athanassios Vassilopoulos
NIDDK/NIH, Visiting Postdoctoral Fellow
Cell cycle, cancer stem cells
vassiloa@niddk.nih.gov
- Chemoprevention
George John Tsioulias
Mount Sinai School of Medicine, Clinical Assistant Professor
Cancer chemoprevention using animal models and clinical trials. cancer chemoprevention using animal models and clinical trials
tsiouliasg@hotmail.com
- Colon & Breast Cancer
Panos Papagiorgis
Boston University, PhD student in Genetics
ppapageo@bu.edu
- Endocrine Cancers
Nicholas J. Sarlis
Sanofi-Aventis, Medical Director, Oncology
Head & Neck Oncology, Taxane Clinical Pharmacology, Oncology Clinical Protocol Management, Drug Development
nicholas.sarlis@sanofi-aventis.com
- Genomic Alterations
Theodore G. Krontiris
Professor of Molecular Medicine
City of Hope Comprehensive Cancer Center, Director
Executive Vice-President for Medical & Scientific Affairs
tkrontiris@coh.org
- Head & Neck Cancer
Alexandros Georgolios
MD, Head and neck cancer, Genetics of Hearing loss
ageorgol@hotmail.com
Nicholas J. Sarlis
Sanofi-Aventis, Medical Director, Oncology
Head & Neck Oncology, Taxane Clinical Pharmacology, Oncology Clinical Protocol Management, Drug Development
nicholas.sarlis@sanofi-aventis.com
- Infectious Diseases
Dimitrios P. Kontoyiannis
The University of Texas MD Anderson Cancer Center, Associate Professor
Opportunistic Infections, Medical Mycology, Experimental Pharmacology, Molecular Mechanisms of Drug Resistance
dkontoyi@mdanderson.org
- Inflammation
Elias Gounaris
Dana Farber Cancer Institute, Research Fellow
Inflammation and cancer
Elias_Gounaris@dfci.harvard.edu
- Internal Medicine
Markos G Kashiouris
Johns Hopkins -- Sinai Hospital, Internal Medicine PGY1
Internal Medicine, Hematology/Oncology
- Invasion
Matthildi Valianou
Fox Chase Cancer Center, Research Associate
Identification and functional analysis of the murine fibroblast activation protein promoter region.
The long term goal is to identify regulators and function of this selectively expressed serine protease.
FAP has a tight expression pattern making it an elegant target for cancer therapy.
m_valianou@fccc.edu
- Leukemia & Multiple Myeloma
Efstratios Katsoulidis, Ph.D.
Northwestern University, Research Assistant Professor
Biological Chemistry, Cancer, Hematology, Immunology
-katsoulidis@northwestern.edu
Anastasios Raptis
raptisa@upmc.edu
- Lung Cancer
Konstantinos Arnaoutakis
Tufts University, Hematology-Oncology fellow
Supportive care clinical research , Bone health , Lung Cancer
karnaoutakis@massmed.org
Joanna Floros, PhD
Pennsylvania State University College of Medicine, Evan Pugh Professor of Pediatrics and Obstetrics & Gynecology, Director of The Penn State Center for Host
defense, Inflammation and Lung Disease (CHILD) Research
jfloros@psu.edu
DNA methylation of host defense molecules
Alexander Pertsemlidis
UT Southwestern Medical Center, Assistant Professor
We are interested in computational biology, specifically in identifying and characterizing mutations relevant to disease, and in microRNA roles in
cholesterol homeostasis and lung cancer pathogenesis
Alexander.Pertsemlidis@UTSouthwestern.edu
Vassiliki Saloura, MD
Hahnemann University Hospital, Resident
Oncolytic virotherapy in lung cancer and mesothelioma, molecular predictors of sensitivity to chemotherapy and personalized approach for chemotherapy in cancer
valsaloura@yahoo.com
- Malignant Mesothelioma
Poulikos Poulikakos
Memorial Sloan-Kettering Cancer Center, Research Fellow
poulikap@mskcc.org
Vassiliki Saloura, MD
Hahnemann University Hospital, Resident
Oncolytic virotherapy in lung cancer and mesothelioma, molecular predictors of sensitivity to chemotherapy and personalized approach for chemotherapy in cancer
valsaloura@yahoo.com
- Molecular Genetics
Nektarios Barabutis, MSc, PhD
Miami MIller School of Medicine, University of Miami, Postdoctoral fellow
Modifications of erythrocyte membrane proteins in patients with hereditary spaerocytosis.
Oxidative alterations of erythrocyte proteins in diabetic patients
The role of Reactive Oxygen Species (ROS) and Reactive Nitrogen Species (RNS) in cell physiology and metabolism.
The role and Signaling of Growth Hormone Releasing Hormone (GHRH) in cancer.
Effect of GHRH in ROS/RNS metabolism.
The role of Luteinizing Hormone Releasing Hormone (LHRH) in cancer and benign prostatic hyperplasia.
The role of GHRH agonistic and antagonistic analogs in human metabolism and disease.
nbarabutis@gmail.com
Vasileios Roukos
National Cancer Institute, National Institutes of Health, Post-doctoral fellow
Nuclear architecture and genome integrity
roukosv@mail.nih.gov
Sotirios G. Stergiopoulos
Harvard University School of Medicine, Clinical and Research Fellow
Cancer, Molecular Genetics
SGSTERGIOPOULOS@PARTNERS.ORG
- Nutrition
Maria Chondronikola
New York University, Graduate Student
Cancer, Nutrition
mc3128@nyu.edu
- Ocular Melanoma
Athanasios Papakostas
Massachusetts Eye & Ear Infirmary/ Harvard Medical School
THE ROLE OF MULLERIAN INHIBITING SUBSTANCE IN THE TREATMENT OF OCULAR MELANOMA-SNP ARRAY IN OCULAR MELANOMA
thanos_papakostas@meei.harvard.edu
- Ovarian Cancer
Angeliki Magklara
NIH/NCI
magklara@mail.nih.gov
- Pediatrics
Sosipatros A. Boikos
National Institute of Child Health and Human Development, National Institutes of Health, Research Associate Investigator-Post-doctoral fellow
Paediatric Endocrinology and Genetics, Cancer Cytogenetics,Carney Complex Syndrome
boikosso@mail.nih.gov
- Regulation of Apoptosis
Evripidis Gavathiotis
Dana-Farber Cancer Institute/Children's Hospital Boston, Harvard Medical School, Instructor
We study the structure and function of apoptotic protein interactions that regulate life and death decisions in the cell. We aim to develop novel pharmacological
strategies and compounds to prevent protein interactions that cause cancer and cardiovascular disease and translate them into therapies.
We employ a multidisciplinary approach spanning chemistry, structural biology, biochemistry, cell biology and in vivo studies.
evripidis_gavathiotis@dfci.harvard.edu
Antonis S. Zervos
University of Central Florida, Professor of Molecular Biology
azervos@mail.ucf.edu
- Stem cell therapy
Andreas Androutsellis-Theotokis
NINDS/NIH, Staff Scientist
Neural Stem Cells, Signal Transduction, Neuro-degenerative disease
My focus is on signal transduction pathways that are of particular importance to stem cells. The purpose of this focus is to identify mechanisms that activate
endogenous stem cells (for the purpose of regenerative interventions) and provide targets for novel anti-cancer approaches
AndreasTheotokis@gmail.com
Christos Tzimas
University of Pennsylvania, Post doctoral fellow
Cancer stem cells
chtzimas@gmail.com
- Vaccine development
Emmanuel Katsanis
University of Arizona Health Center, Professor
Department of Pediatrics
A novel anti-cancer vaccine has been developed in the laboratory (called Chaperone Rich Cell Lysate or CRCL) that has been shown to be effective
against a variety of tumors in mice. CRCL has a more pronounced immunologic effect per unit of protein than any of the individual HSP vaccines
currently used in clinical trials. We have found that it can stimulate potent tumor-specific T cell responses against a variety of tumors in mice.
Furthermore it has intrinsic adjuvant activity capable of stimulating both natural killer (NK) cells and dendritic cells (DC). Moreover, it can protect these
cells from regulatory T cell immunosuppression. Since tumor-derived CRCL vaccines are effective against a wide range of tumor types in mice, we have
embarked on in vitro human studies to confirm our findings. We have demonstrated that CRCL can be used effectively to pulse DCs and to generate
specific T cells against human cancer. This personalized vaccine is a promising approach for active cancer immunotherapy and merits further study in
humans.
- Waldenstrom’s Macroglobulinemia
Thea Ioakimidis
Dana Farber Cancer Institute, Researcher
Pharmaceutical Science
leukothea_ioakimidis@dfci.harvard.edu
- Wnt signaling
Meletios Verras
Stanford University, Postdoctoral fellow
Role of Wnt/beta-catenin signaling pathway in cancer
mverras@stanford.edu
- Other
Ourania Andrisani
Purdue University, Professor
Signal transduction mechanisms mediating liver and prostate cancer; signal transduction mechanisms involved in neural crest cell differentiation
andrisao@purdue.edu
Anastasia Kalea
Feinberg School of Medicine-Northwestern University, Postdoctoral Research Fellow
Diabetes complications; Trace minerals; Functional Foods; Vascular structure and function; Cancer, Public Health
a-kalea@northwestern.edu
David G Kalergis
Diffusion Pharmaceuticals LLC, CEO
Developing novel small molecules for the treatment of hypoxia related to ischemic conditions
dkalergis@diffusionpharma.com
Spiros P. Katsifis
University of Bridgeport, Professor and Chair
Metal interaction of physical and chemical agents in the induction of DNA damage. In Vitro mutagenesis - carcinogenesis
skatsif@bridgeport.edu
Stephanos Pavlides
Thomas Jefferson University, PhD candidate
Animal Science, Metabolic Diseases, Pulmonary Diseases, Cancer, Cardiovascular Disease, Muscle research, Pharmacology
spavlidescy@gmail.com
Hellenic Bioscientific Association in the USA
HBA-USA
HBA-USA
 | |  | |  | |  | |  | |  | |  | |  | |  |